Summary

The global biosurgery market represents a critical segment of the medical device industry, driven by the rising prevalence of chronic diseases, increasing surgical volumes, rapid population aging, and expanding adoption of advanced surgical biomaterials. Biosurgery encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications. By restoring tissue integrity and reducing surgical complications through specialized biomaterials, biosurgery improves clinical outcomes, enhances patient recovery, reduces hospital stays, and lowers healthcare costs. According to the World Health Organization (WHO), an estimated 313 million surgical procedures are performed globally each year. Surgical conditions contribute to approximately 30% of the global burden of disease. According to the WHO, the global population aged 60 years and older is expected to reach 2.1 billion by 2050, significantly increasing demand for orthopedic and other surgical interventions. According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes globally in 2021, and this number is projected to rise to 643 million by 2030, directly increasing demand for biosurgery products in wound care and surgical management. According to the research report, "Global Biosurgery Market Outlook, 2031," published by Bonafide Research, the Global Biosurgery Market is expected to cross Global 25.08 Billion market size by 2031, with 6.13% CAGR by 2026-31.. Market expansion is supported by continuous technological innovation, increasing availability of advanced surgical technologies, growing awareness of evidence-based surgical care, and broader adoption of biosurgical products across developed and emerging healthcare markets. According to the Organisation for Economic Co-operation and Development (OECD), healthcare spending as a share of GDP continued to rise across member nations following the COVID-19 pandemic, supporting increased procurement of advanced surgical and biosurgery products. North America currently dominates the global market due to its advanced healthcare infrastructure, favorable reimbursement environment, high surgical volumes, and strong adoption of biosurgical technologies. Meanwhile, the Asia-Pacific region is expected to register the fastest growth during the forecast period, driven by its large patient population, rapid healthcare modernization, expanding surgical capacity, and improving access to advanced surgical therapies. The global supply chain for biosurgical products operates within a highly regulated medical device ecosystem requiring rigorous clinical validation, quality assurance, and post-market surveillance. Leading manufacturers including Johnson & Johnson (Ethicon), Baxter International, Medtronic, Becton Dickinson (BD), and B. Braun Melsungen AG continue to strengthen their market positions through continuous innovation in hemostatic agents, surgical sealants, bone-graft substitutes, and adhesion barriers. Johnson & Johnson MedTech reported $33.8 billion in sales in 2025, with operational sales growth of 5.4% driven by wound-closure products in general surgery. Medtronic reported FY25 worldwide revenue of $33.537 billion, with its Medical Surgical portfolio contributing $8.407 billion. Increasing digitalization of surgical care, expansion of ambulatory surgical centers, and integration of advanced biomaterials are further enhancing surgical outcomes and improving healthcare efficiency across global markets. Market Drivers • Rising global burden of chronic diseases and surgical procedures: The increasing prevalence of chronic diseases remains the primary driver of the global biosurgery market. Surgical conditions contribute to approximately 30% of the global burden of disease. An estimated 313 million surgical procedures are performed globally each year. Aging populations, improved survival following chronic diseases, and the growing incidence of hypertension, diabetes, obesity, and orthopedic conditions have significantly expanded the number of patients requiring surgical interventions worldwide. According to the WHO, the global population aged 60 years and older is expected to reach 2.1 billion by 2050, significantly increasing demand for orthopedic and other surgical interventions. According to the IDF, approximately 537 million adults were living with diabetes globally in 2021, projected to rise to 643 million by 2030, directly increasing demand for biosurgery products in wound care and surgical management. • Technological advancements and expanding surgical infrastructure: Continuous innovation in biomaterials and surgical delivery systems is significantly supporting global biosurgery adoption. Manufacturers are introducing next-generation hemostatic agents with faster action times, synthetic sealants with enhanced wet-tissue adhesion, bioactive bone grafts with regenerative capabilities, and absorbable adhesion barriers that improve procedural success, patient safety, and long-term outcomes. According to the OECD, healthcare spending as a share of GDP continued to rise across member nations following the COVID-19 pandemic, supporting increased procurement of advanced surgical and biosurgery products. Simultaneously, healthcare systems are expanding hospitals, ambulatory surgical centers, specialized surgical facilities, and physician training programs, enabling greater availability of advanced surgical procedures. Johnson & Johnson MedTech's 2025 sales growth of 5.4% to $33.8 billion was driven by wound-closure products in general surgery. Market Challenges • High product costs and pricing pressure: Despite the market's size and growth potential, biosurgery manufacturers face significant challenges from high product costs and pricing pressure across all regions. Premium biologic grafts and advanced sealants can cost $500–$3,000+ per unit, limiting adoption in price-sensitive markets. In emerging economies, public healthcare systems face budget constraints that restrict access to premium biosurgical products. In developed markets, hospital procurement organizations, group purchasing organizations (GPOs), and government payers exert persistent pricing pressure. Manufacturers must continually demonstrate both clinical efficacy and cost-effectiveness to justify premium pricing in an increasingly cost-conscious global healthcare system. According to WHO, access to safe, timely, and affordable surgical care remains profoundly inequitable, particularly in low- and middle-income countries (LMICs), where patients frequently encounter substantially higher perioperative risks owing to weak health systems, insufficient infrastructure, and limited workforce capacity. • Regulatory complexity and compliance burdens: The global biosurgery market faces significant challenges from regulatory fragmentation and varying compliance standards across regions. The European Medical Device Regulation (MDR) requires more rigorous clinical evidence and stricter post-market surveillance, creating barriers for both established players and emerging competitors. Asia-Pacific's diverse regulatory landscape presents compliance burdens across China's NMPA, Japan's PMDA, India's CDSCO, and Southeast Asian authorities. Latin America's regulatory fragmentation across ANVISA (Brazil), ANMAT (Argentina), and INVIMA (Colombia) increases time-to-market and compliance costs. The Lancet Commission on Global Surgery has recommended indicators such as surgical volume and perioperative mortality to enable countries to track performance and identify bottlenecks in surgical service delivery. Navigating these varying requirements increases costs and extends time-to-market for innovative biosurgical products. Market Trends • Accelerating shift to ambulatory surgical centers and outpatient settings: The global biosurgery market is undergoing a fundamental structural transformation as surgical care continues its long-term migration from inpatient hospitals to ambulatory surgical centers (ASCs) and outpatient settings. According to the U.S. Centers for Medicare & Medicaid Services (CMS), the agency finalized plans to substantially expand the list of procedures outpatient surgery centers are allowed to perform, shifting more surgical procedures away from the traditional hospital setting. This shift is driven by technological advances enabling more complex procedures to be performed safely in outpatient settings, patient preference for convenience, and payer initiatives to reduce healthcare expenditure. For biosurgery manufacturers, this trend requires adaptation of product portfolios developing formulations and delivery systems optimized for the fast-paced, high-throughput ASC environment and adjustment of commercial strategies to target the growing ASC customer base. • Growing adoption of minimally invasive and robotic-assisted surgery: Healthcare systems globally are rapidly adopting minimally invasive and robotic-assisted surgical techniques. Continuous quality improvement mechanisms rooted in measurable performance indicators, regular audits, and structured feedback loops have proven to be effective in raising care standards. The WHO's Safe Surgery Saves Lives initiative has played a pivotal role in promoting the adoption of safety checklists to minimize surgical errors and reduce avoidable harm. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand. Digital innovations, including big data analytics, electronic health records, and national surgical registries, are helping identify high-risk patients and improve surgical outcomes. Surgical Sealants and Adhesives is the fastest-growing product segment because increasing adoption of minimally invasive and robotic surgical techniques across all regions creates global demand for advanced tissue-sealing solutions that can be delivered through small incisions. Surgical Sealants and Adhesives represent the fastest-growing product category in the global biosurgery market, driven by the accelerating adoption of minimally invasive and robotic surgical techniques across all regions. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. This shift toward advanced surgical platforms creates new opportunities for surgical sealants and adhesives that can be delivered through small incisions. Continuous product innovation, including synthetic sealants with enhanced wet-tissue adhesion and faster polymerization times, is expanding the addressable market and creating new clinical applications across cardiovascular, general, and thoracic surgeries. North America leads in the adoption of these advanced technologies, while Asia-Pacific represents the fastest-growing market for surgical sealants and adhesives. Bone-Graft Substitutes is the largest product segment because high volumes of spinal fusion procedures, joint replacements, and orthopedic trauma surgeries across all regions drive sustained global demand for musculoskeletal repair solutions. Bone-Graft Substitutes represent the largest product category in the global biosurgery market, driven by the high volume of spinal fusion procedures, joint replacements, and orthopedic trauma surgeries across all regions. According to the German Federal Statistical Office (Destatis), 16,531,491 surgical procedures were performed on full inpatient hospital patients in Germany in 2023. According to the German Endoprosthesis Register (EPRD), 410,333 endoprosthetic procedures on hip or knee were performed in Germany in 2024, the highest number ever recorded. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging global population with over 1.2 billion people aged 60 or over and projected to reach 2.1 billion by 2050 continues to drive demand for musculoskeletal interventions. Technological innovations, including synthetic bone substitutes and bioactive grafts incorporating growth factors, are expanding treatment options and improving clinical outcomes across orthopedic and neurosurgical procedures. Cardiovascular Surgery is the fastest-growing application segment because rising global cardiovascular disease prevalence, aging populations, and technological advancements in cardiac procedures are increasing worldwide demand for vascular sealants, hemostatic agents, and soft-tissue attachments. Cardiovascular Surgery represents the fastest-growing application area in the global biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures, including coronary artery bypass grafting, valve replacements, and vascular reconstructions. The growing adoption of minimally invasive cardiac surgery techniques across all regions is creating new opportunities for advanced biosurgical products designed for smaller incisions and precision delivery. The increasing burden of cardiovascular disease, combined with the aging population and rising prevalence of risk factors such as obesity and diabetes, is expected to sustain strong demand for biosurgical products in this application. Orthopedic Surgery is the largest application segment because high volumes of joint replacements, spinal fusions, and trauma procedures across all regions create sustained global demand for biosurgical products across musculoskeletal interventions. Orthopedic Surgery is the largest application area for biosurgical products globally, driven by the high volume of joint replacement, spinal fusion, and trauma procedures. Germany's EPRD reported 410,333 endoprosthetic procedures on hip or knee in 2024 the highest number ever recorded. The aging global population with over 1.2 billion people aged 60 or over and projected to reach 2.1 billion by 2050 continues to drive demand for musculoskeletal interventions. The increasing prevalence of osteoarthritis, osteoporosis, and sports-related injuries further supports sustained demand for biosurgical products in this application. Bone-graft substitutes are the primary biosurgical products utilized in this specialty, supplemented by hemostatic agents and soft-tissue attachments. Synthetic and Semi-Synthetic products are the fastest-growing source category because cost-effectiveness, consistent quality, lower immunogenicity risks, and growing domestic manufacturing capabilities support adoption across price-sensitive healthcare markets globally. Synthetic and Semi-Synthetic products represent the fastest-growing source category in the global biosurgery market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and rapidly expanding domestic manufacturing capabilities. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The growing emphasis on cost-containment in healthcare systems globally favors synthetic alternatives for certain applications. The emphasis on cost-effectiveness in healthcare systems, combined with consistent quality and reduced immunogenicity risks, supports the growing adoption of synthetic alternatives across all regions. Asia-Pacific is expected to witness the fastest growth in synthetic biosurgical products, driven by cost sensitivity and growing domestic manufacturing capabilities. Biologic products are the largest source category because their superior biocompatibility, natural healing properties, and surgeon preference support widespread adoption across surgical specialties globally. Biologic products represent the largest source category in the global biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. Surgeons globally prefer biologic materials due to their ability to promote natural healing and integration with human tissue. Regulatory requirements for biological materials ensure high safety standards and support market confidence. The aging population and increasing volume of orthopedic and cardiovascular procedures further support demand for biologic products. Ambulatory Surgical Centers are the fastest-growing end-user segment because the global shift toward outpatient and same-day discharge models, cost-efficiency, and technological advancements are increasing procedure volumes in ASC settings worldwide. Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the global biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. According to the U.S. Centers for Medicare & Medicaid Services (CMS), the agency finalized plans to substantially expand the list of procedures outpatient surgery centers are allowed to perform, shifting more surgical procedures away from the traditional hospital setting. Technological advances enabling more complex procedures to be performed safely in outpatient settings, patient preference for convenience, and payer initiatives to reduce healthcare expenditure are driving ASC growth globally. For biosurgery manufacturers, this trend requires adaptation of product portfolios developing formulations and delivery systems optimized for the fast-paced, high-throughput ASC environment and adjustment of commercial strategies to target the growing ASC customer base. Hospitals remain the largest end-user segment because the concentration of complex surgical procedures, availability of specialized surgical teams, and intensive care facilities make hospitals the primary setting for biosurgical product utilization globally. Hospitals remain the largest end-user segment for biosurgical products globally, accounting for the majority of revenue. The hospitals segment accounted for the largest revenue share in the global biosurgery market in 2025, owing to increasing number of general and gynecological surgeries being performed across multi-specialty hospital facilities. The concentration of complex surgical procedures, availability of specialized surgical teams, and intensive care facilities make hospitals the primary setting for biosurgical product utilization. The aging population and increasing volume of complex surgical procedures, including cardiovascular, neurological, and orthopedic surgeries, ensure continued hospital dominance in biosurgical product consumption. North America dominates the global biosurgery market because advanced healthcare infrastructure, high surgical procedure volumes, robust reimbursement systems, and the presence of key market players support widespread biosurgical product utilization. North America represents the largest regional biosurgery market, driven by its advanced healthcare ecosystem, high surgical volumes, and strong presence of global medical device manufacturers. According to the U.S. Centers for Medicare & Medicaid Services (CMS), the agency substantially expanded the list of procedures outpatient surgery centers are allowed to perform, shifting more surgical procedures away from the traditional hospital setting. The region benefits from established reimbursement mechanisms through CMS and private insurers in the United States, widespread availability of specialized surgical centers, and strong adoption of guideline-based treatment pathways. North America accounts for approximately 44.36% of the global biosurgery market, with the United States representing 87.42% of the regional share. Continuous innovation in biosurgery technologies, including advanced hemostatic agents, synthetic sealants, and bioactive bone grafts, is further supporting market expansion. Asia-Pacific is the fastest-growing region because massive surgical volumes, rapid healthcare infrastructure expansion, aging populations, and government policies promoting domestic manufacturing are driving accelerated biosurgery market development. Asia-Pacific represents the fastest-growing biosurgery market globally, driven by the region's massive surgical volumes, rapid healthcare infrastructure expansion, and large aging populations. According to the National Health Commission of China, the country's surgical procedures have been growing rapidly, with surgical methods continuously improving. The region accounts for approximately 29.90% of the global biosurgery market. Regulatory modernization across the region, including China's NMPA innovative device review process, Japan's PMD Act amendments, South Korea's Digital Medical Products Act, and India's National Medical Devices Policy, is facilitating faster market access for innovative biosurgical products. Asia-Pacific is expected to maintain the fastest growth rate during the forecast period. Europe contributes significantly to the global biosurgery market with established healthcare systems and expanding surgical capacity. Europe represents a mature biosurgery market accounting for approximately 19.66% of the global market. According to the German Federal Statistical Office (Destatis), 16,531,491 surgical procedures were performed on full inpatient hospital patients in Germany in 2023. Healthcare expenditure in Germany reached EUR 579.5 billion in 2025. According to the German Endoprosthesis Register (EPRD), 410,333 endoprosthetic procedures on hip or knee were performed in Germany in 2024, the highest number ever recorded. The regulatory environment, centered on the European Medical Device Regulation (MDR) and national competent authorities, plays a decisive role in shaping market dynamics across the region. • July 2026: EQT agreed to acquire Corza Biosurgery, the manufacturer of TachoSil®, a leading hemostatic and sealing patch, from Corza Medical. The transaction is expected to close during Q4 2026, with EQT planning to invest in commercial acceleration and geographic expansion. • April 2026: BIOTRONIK announced U.S. FDA approval for its Acticor Sky and Rivacor Sky implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The Sky device family expands the company's cardiac rhythm portfolio with technologies designed to support physiology-driven therapies and improve clinical workflows. • April 2026: Abbott presented four late-breaking clinical studies at the Heart Rhythm Society (HRS) 2026 meeting in Chicago, highlighting clinical evidence across its pulsed field ablation technologies and novel cardiac pacing portfolio, including conduction system pacing innovations. • March 2026: Medtronic received U.S. FDA approval for an expanded indication of its OmniaSecure™ defibrillation lead, allowing placement in the left bundle branch area for conduction system pacing when connected to ICD or CRT-D systems. • February 2026: BIOTRONIK launched the Acticor Sky and Rivacor Sky device family across CE markets, introducing the world's first CE-approved high-voltage device supporting left bundle branch area pacing (LBBAP) within ICD and CRT-D systems. • December 2025: Solventum completed the acquisition of Acera Surgical, a privately held bioscience company focused on developing engineered materials for regenerative wound care. The acquisition expands Solventum's MedSurg portfolio into the synthetic tissue matrices technology space in acute care settings. • December 2025: The FDA cleared TRAUMAGEL® 2.0 Hemostatic Gel (K253609), a hemostatic gel indicated for temporary external use for controlling moderate to severe bleeding. • December 2025: The FDA cleared MFUSE™, a sterile, single-use, disposable hemostatic hydrogel paste for temporary external use for controlling moderate to severe bleeding. • November 2025: The FDA cleared XSTAT P15 (K253290), a hemostatic wound dressing for emergency trauma control. • September 2025: The FDA cleared FG Bone Graft M (K244006), intended for use as a bone grafting material to fill, augment or reconstruct periodontal or oral/maxillofacial defects. • September 2025: Baxter's Preveleak Surgical Sealant received FDA PMA supplement approval (P100030 S021). • August 2025: The FDA cleared FG Bone Graft B (K243745). • July 2025: The FDA approved SURGIFLO® Hemostatic Matrix, an absorbable hemostatic agent. • July 2025: Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies, expanding its robotics suite with autonomous solutions. The acquisition is expected to be neutral to adjusted earnings per share in 2025–2027 and accretive thereafter. • June 2025: Cerapedics Inc. received FDA premarket approval for its PearlMatrix™ P-15 Peptide Enhanced Bone Graft, the first and only bone growth accelerator proven to accelerate lumbar fusion based on data from the pivotal ASPIRE IDE study. • June 2025: Aroa Biosurgery Ltd. received FDA 510(k) clearance for Endoform™ Reconstructive Template – PLGA, intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. • June 2025: The FDA cleared Grafton™ DBM (K251193). • May 2025: Johnson & Johnson MedTech announced the U.S. introduction of MENTOR™ MemoryGel™ Enhance Breast Implants, addressing a vital need in complete breast cancer treatment for women who have had a mastectomy. • May 2025: Baxter introduced Hemopatch Sealing Hemostat, a collagen-based pad featuring a dual-action system that merges a collagen matrix with a reactive NHS-PEG coating for enhanced hemostatic capabilities. The revised formulation permits storage at room temperature and extends shelf life to three years. • April 2025: Restor3D, a firm focused on 3D-printed, custom orthopedic implants, secured $38 million in growth funding to accelerate its expansion and introduce four new product lines over the next two years, including the Veritas shoulder, iTotal Identity knee, Kinos ankle, and Velora hip cup. • April 2025: simAbs opened a new GMP cleanroom facility in collaboration with Sealantium Medical, a biosurgery enterprise dedicated to creating next-generation tissue sealants and hemostatic agents for surgical patients. • April 2025: The U.S. FDA granted Premarket Approval (PMA) for the WiSE CRT System, the world's first leadless left ventricular endocardial pacing system for cardiac resynchronization therapy (CRT), enabling leadless LV pacing for eligible heart failure patients. • April 2025: Ventris Medical secured additional FDA clearance for Backpack® Bone Graft in intervertebral disc applications. • March 2025: Olympus announced the introduction of the Retentia™ HemoClip, a new hemostasis clip featuring 360° rotation and a user-friendly one-step deployment, available in three sizes to suit various closure needs. • March 2025: Teleflex announced a definitive agreement to acquire substantially all of BIOTRONIK's Vascular Intervention business for approximately €760 million in cash. • March 2025: The FDA cleared QuikClot Control+ Hemostatic Device (K243553). • February 2025: The FDA cleared Synthetic Bone Graft Particulate (K241186). • February 2025: The FDA cleared Resolution Clip (K250066). • January 2025: Kuros Biosciences USA, Inc. entered into an exclusive strategic agreement with Medtronic's Spinal Division, appointing Medtronic as the exclusive sales agent for MagnetOs in designated territories for spinal surgery applications. • January 2025: Royal Biologics signed an exclusive distribution agreement with Aroa Biosurgery for Myriad Matrix™ Restore, expanding access to advanced soft tissue repair solutions across outpatient and mobile care settings in the U.S. • January 2025: Aroa Biosurgery published additional robust clinical evidence supporting both the effectiveness and cost advantages of its AROA ECM™ technology in high-risk limb salvage surgery. The single-site prospective clinical study involved 130 complex lower limb defects from 120 patients, with 95% of participants having at least one risk factor for lower limb amputation. • January 2025: The FDA expanded the indication of ARTISS for use in adult and pediatric patients to adhere autologous skin grafts to surgically prepared wound beds resulting from burns and to adhere tissue flaps during facial rhytidectomy surgery. • January 2025: The FDA expanded the indication of TISSEEL for use in adult and pediatric patients as an adjunct to hemostasis and to prevent leakage from colonic anastomoses following the reversal of temporary colostomies.May 2023: BIOTRONIK received CE approval for the Amvia Sky and Amvia Edge pacemaker family, including CRT-P models approved for left bundle branch area pacing (LBBAP), expanding support for physiologic pacing therapies. Considered in this report • Historic Year: 2020 • Base year: 2025 • Estimated year: 2026 • Forecast year: 2031 Aspects covered in this report • Biosurgery Market with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Product • Bone-Graft Substitutes • Hemostatic Agents • Surgical Sealants & Adhesives • Adhesion Barriers • Soft-Tissue Attachments • Staple-Line Reinforcement By Application: • Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more) By Source/Origin • Biologic • Synthetic / Semi-synthetic By End-user: • Hospitals • Ambulatory Surgical Centers • Clinics • Others ***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents

Table of Content



1. Executive Summary

2. Market Dynamics

2.1. Market Drivers & Opportunities

2.2. Market Restraints & Challenges

2.3. Market Trends

2.4. Supply chain Analysis

2.5. Policy & Regulatory Framework

2.6. Industry Experts Views

3. Research Methodology

3.1. Secondary Research

3.2. Primary Data Collection

3.3. Market Formation & Validation

3.4. Report Writing, Quality Check & Delivery

4. Market Structure

4.1. Market Considerate

4.2. Assumptions

4.3. Limitations

4.4. Abbreviations

4.5. Sources

4.6. Definitions

5. Economic /Demographic Snapshot

6. Global Biosurgery Market Outlook

6.1. Market Size By Value

6.2. Market Share By Region

6.3. Market Size and Forecast, By Geography

6.4. Market Size and Forecast, By Product

6.5. Market Size and Forecast, By Application

6.6. Market Size and Forecast, By Source/Origin

6.7. Market Size and Forecast, By End-User

7. North America Biosurgery Market Outlook

7.1. Market Size By Value

7.2. Market Share By Country

7.3. Market Size and Forecast, By Product

7.4. Market Size and Forecast, By Application

7.5. Market Size and Forecast, By Source/Origin

7.6. Market Size and Forecast, By End-User

7.7. United States Biosurgery Market Outlook

7.7.1. Market Size by Value

7.7.2. Market Size and Forecast By Product

7.7.3. Market Size and Forecast By Application

7.7.4. Market Size and Forecast By Source/Origin

7.7.5. Market Size and Forecast By End-User

7.8. Canada Biosurgery Market Outlook

7.8.1. Market Size by Value

7.8.2. Market Size and Forecast By Product

7.8.3. Market Size and Forecast By Application

7.8.4. Market Size and Forecast By Source/Origin

7.8.5. Market Size and Forecast By End-User

7.9. Mexico Biosurgery Market Outlook

7.9.1. Market Size by Value

7.9.2. Market Size and Forecast By Product

7.9.3. Market Size and Forecast By Application

7.9.4. Market Size and Forecast By Source/Origin

7.9.5. Market Size and Forecast By End-User

8. Europe Biosurgery Market Outlook

8.1. Market Size By Value

8.2. Market Share By Country

8.3. Market Size and Forecast, By Product

8.4. Market Size and Forecast, By Application

8.5. Market Size and Forecast, By Source/Origin

8.6. Market Size and Forecast, By End-User

8.7. Germany Biosurgery Market Outlook

8.7.1. Market Size by Value

8.7.2. Market Size and Forecast By Product

8.7.3. Market Size and Forecast By Application

8.7.4. Market Size and Forecast By Source/Origin

8.7.5. Market Size and Forecast By End-User

8.8. United Kingdom (UK) Biosurgery Market Outlook

8.8.1. Market Size by Value

8.8.2. Market Size and Forecast By Product

8.8.3. Market Size and Forecast By Application

8.8.4. Market Size and Forecast By Source/Origin

8.8.5. Market Size and Forecast By End-User

8.9. France Biosurgery Market Outlook

8.9.1. Market Size by Value

8.9.2. Market Size and Forecast By Product

8.9.3. Market Size and Forecast By Application

8.9.4. Market Size and Forecast By Source/Origin

8.9.5. Market Size and Forecast By End-User

8.10. Italy Biosurgery Market Outlook

8.10.1. Market Size by Value

8.10.2. Market Size and Forecast By Product

8.10.3. Market Size and Forecast By Application

8.10.4. Market Size and Forecast By Source/Origin

8.10.5. Market Size and Forecast By End-User

8.11. Spain Biosurgery Market Outlook

8.11.1. Market Size by Value

8.11.2. Market Size and Forecast By Product

8.11.3. Market Size and Forecast By Application

8.11.4. Market Size and Forecast By Source/Origin

8.11.5. Market Size and Forecast By End-User

8.12. Russia Biosurgery Market Outlook

8.12.1. Market Size by Value

8.12.2. Market Size and Forecast By Product

8.12.3. Market Size and Forecast By Application

8.12.4. Market Size and Forecast By Source/Origin

8.12.5. Market Size and Forecast By End-User

9. Asia-Pacific Biosurgery Market Outlook

9.1. Market Size By Value

9.2. Market Share By Country

9.3. Market Size and Forecast, By Product

9.4. Market Size and Forecast, By Application

9.5. Market Size and Forecast, By Source/Origin

9.6. Market Size and Forecast, By End-User

9.7. China Biosurgery Market Outlook

9.7.1. Market Size by Value

9.7.2. Market Size and Forecast By Product

9.7.3. Market Size and Forecast By Application

9.7.4. Market Size and Forecast By Source/Origin

9.7.5. Market Size and Forecast By End-User

9.8. Japan Biosurgery Market Outlook

9.8.1. Market Size by Value

9.8.2. Market Size and Forecast By Product

9.8.3. Market Size and Forecast By Application

9.8.4. Market Size and Forecast By Source/Origin

9.8.5. Market Size and Forecast By End-User

9.9. India Biosurgery Market Outlook

9.9.1. Market Size by Value

9.9.2. Market Size and Forecast By Product

9.9.3. Market Size and Forecast By Application

9.9.4. Market Size and Forecast By Source/Origin

9.9.5. Market Size and Forecast By End-User

9.10. Australia Biosurgery Market Outlook

9.10.1. Market Size by Value

9.10.2. Market Size and Forecast By Product

9.10.3. Market Size and Forecast By Application

9.10.4. Market Size and Forecast By Source/Origin

9.10.5. Market Size and Forecast By End-User

9.11. South Korea Biosurgery Market Outlook

9.11.1. Market Size by Value

9.11.2. Market Size and Forecast By Product

9.11.3. Market Size and Forecast By Application

9.11.4. Market Size and Forecast By Source/Origin

9.11.5. Market Size and Forecast By End-User

10. South America Biosurgery Market Outlook

10.1. Market Size By Value

10.2. Market Share By Country

10.3. Market Size and Forecast, By Product

10.4. Market Size and Forecast, By Application

10.5. Market Size and Forecast, By Source/Origin

10.6. Market Size and Forecast, By End-User

10.7. Brazil Biosurgery Market Outlook

10.7.1. Market Size by Value

10.7.2. Market Size and Forecast By Product

10.7.3. Market Size and Forecast By Application

10.7.4. Market Size and Forecast By Source/Origin

10.7.5. Market Size and Forecast By End-User

10.8. Argentina Biosurgery Market Outlook

10.8.1. Market Size by Value

10.8.2. Market Size and Forecast By Product

10.8.3. Market Size and Forecast By Application

10.8.4. Market Size and Forecast By Source/Origin

10.8.5. Market Size and Forecast By End-User

10.9. Colombia Biosurgery Market Outlook

10.9.1. Market Size by Value

10.9.2. Market Size and Forecast By Product

10.9.3. Market Size and Forecast By Application

10.9.4. Market Size and Forecast By Source/Origin

10.9.5. Market Size and Forecast By End-User

11. Middle East & Africa Biosurgery Market Outlook

11.1. Market Size By Value

11.2. Market Share By Country

11.3. Market Size and Forecast, By Product

11.4. Market Size and Forecast, By Application

11.5. Market Size and Forecast, By Source/Origin

11.6. Market Size and Forecast, By End-User

11.7. United Arab Emirates (UAE) Biosurgery Market Outlook

11.7.1. Market Size by Value

11.7.2. Market Size and Forecast By Product

11.7.3. Market Size and Forecast By Application

11.7.4. Market Size and Forecast By Source/Origin

11.7.5. Market Size and Forecast By End-User

11.8. Saudi Arabia Biosurgery Market Outlook

11.8.1. Market Size by Value

11.8.2. Market Size and Forecast By Product

11.8.3. Market Size and Forecast By Application

11.8.4. Market Size and Forecast By Source/Origin

11.8.5. Market Size and Forecast By End-User

11.9. South Africa Biosurgery Market Outlook

11.9.1. Market Size by Value

11.9.2. Market Size and Forecast By Product

11.9.3. Market Size and Forecast By Application

11.9.4. Market Size and Forecast By Source/Origin

11.9.5. Market Size and Forecast By End-User

12. Competitive Landscape

12.1. Competitive Dashboard

12.2. Business Strategies Adopted by Key Players

12.3. Key Players Market Share Insights and Analysis, 2025

12.4. Key Players Market Positioning Matrix

12.5. Porter's Five Forces

12.6. Company Profile

12.6.1. Johnson & Johnson

12.6.1.1. Company Snapshot

12.6.1.2. Company Overview

12.6.1.3. Financial Highlights

12.6.1.4. Geographic Insights

12.6.1.5. Business Segment & Performance

12.6.1.6. Product Portfolio

12.6.1.7. Key Executives

12.6.1.8. Strategic Moves & Developments

12.6.2. Baxter International Inc.

12.6.3. Medtronic plc

12.6.4. Becton, Dickinson & Company (BD)

12.6.5. B. Braun SE

12.6.6. Integra LifeSciences Holdings Corporation

12.6.7. Stryker Corporation

12.6.8. Zimmer Biomet Holdings, Inc.

12.6.9. Artivion, Inc.

12.6.10. Smith & Nephew plc

12.6.11. Orthofix Medical Inc.

12.6.12. Kuros Biosciences AG

12.6.13. Aroa Biosurgery Limited

12.6.14. Tissue Regenix Group plc

12.6.15. Anika Therapeutics, Inc.

12.6.16. Arthrex, Inc.

12.6.17. Corza Medical Inc.

12.6.18. Advanced Medical Solutions Group plc

12.6.19. CSL Behring

12.6.20. Boston Scientific Corporation

13. Strategic Recommendations

14. Annexure

14.1. FAQ`s

14.2. Notes

15. Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Figure



Figure 1: Global Biosurgery Market Size (USD Billion) By Region, 2025 & 2031F

Figure 2: Market attractiveness Index, By Region 2031F

Figure 3: Market attractiveness Index, By Segment 2031F

Figure 4: Global Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 5: Global Biosurgery Market Share By Region (2025)

Figure 6: North America Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 7: North America Biosurgery Market Share By Country (2025)

Figure 8: United States Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 9: Canada Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 10: Mexico Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 11: Europe Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 12: Europe Biosurgery Market Share By Country (2025)

Figure 13: Germany Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 14: United Kingdom (UK) Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 15: France Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 16: Italy Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 17: Spain Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 18: Russia Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 19: Asia-Pacific Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 20: Asia-Pacific Biosurgery Market Share By Country (2025)

Figure 21: China Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 22: Japan Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 23: India Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 24: Australia Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 25: South Korea Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 26: South America Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 27: South America Biosurgery Market Share By Country (2025)

Figure 28: Brazil Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 29: Argentina Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 30: Colombia Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 31: Middle East & Africa Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 32: Middle East & Africa Biosurgery Market Share By Country (2025)

Figure 33: United Arab Emirates (UAE) Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 34: Saudi Arabia Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 35: South Africa Biosurgery Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 36: Porter's Five Forces of Global Biosurgery Market





List of Table



Table 1: Global Biosurgery Market Snapshot, By Segmentation (2025 & 2031F) (in USD Billion)

Table 2: Influencing Factors for Biosurgery Market, 2025

Table 3: Top 10 Counties Economic Snapshot 2024

Table 4: Economic Snapshot of Other Prominent Countries 2022

Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars

Table 6: Global Biosurgery Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)

Table 7: Global Biosurgery Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)

Table 8: Global Biosurgery Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)

Table 9: Global Biosurgery Market Size and Forecast, By Source/Origin (2020 to 2031F) (In USD Billion)

Table 10: Global Biosurgery Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)

Table 11: North America Biosurgery Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)

Table 12: North America Biosurgery Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)

Table 13: North America Biosurgery Market Size and Forecast, By Source/Origin (2020 to 2031F) (In USD Billion)

Table 14: North America Biosurgery Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)

Table 15: United States Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 16: United States Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 17: United States Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 18: United States Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 19: Canada Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 20: Canada Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 21: Canada Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 22: Canada Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 23: Mexico Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 24: Mexico Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 25: Mexico Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 26: Mexico Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 27: Europe Biosurgery Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)

Table 28: Europe Biosurgery Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)

Table 29: Europe Biosurgery Market Size and Forecast, By Source/Origin (2020 to 2031F) (In USD Billion)

Table 30: Europe Biosurgery Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)

Table 31: Germany Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 32: Germany Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 33: Germany Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 34: Germany Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 35: United Kingdom (UK) Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 36: United Kingdom (UK) Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 37: United Kingdom (UK) Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 38: United Kingdom (UK) Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 39: France Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 40: France Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 41: France Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 42: France Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 43: Italy Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 44: Italy Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 45: Italy Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 46: Italy Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 47: Spain Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 48: Spain Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 49: Spain Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 50: Spain Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 51: Russia Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 52: Russia Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 53: Russia Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 54: Russia Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 55: Asia-Pacific Biosurgery Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)

Table 56: Asia-Pacific Biosurgery Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)

Table 57: Asia-Pacific Biosurgery Market Size and Forecast, By Source/Origin (2020 to 2031F) (In USD Billion)

Table 58: Asia-Pacific Biosurgery Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)

Table 59: China Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 60: China Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 61: China Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 62: China Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 63: Japan Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 64: Japan Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 65: Japan Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 66: Japan Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 67: India Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 68: India Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 69: India Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 70: India Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 71: Australia Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 72: Australia Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 73: Australia Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 74: Australia Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 75: South Korea Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 76: South Korea Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 77: South Korea Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 78: South Korea Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 79: South America Biosurgery Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)

Table 80: South America Biosurgery Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)

Table 81: South America Biosurgery Market Size and Forecast, By Source/Origin (2020 to 2031F) (In USD Billion)

Table 82: South America Biosurgery Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)

Table 83: Brazil Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 84: Brazil Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 85: Brazil Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 86: Brazil Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 87: Argentina Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 88: Argentina Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 89: Argentina Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 90: Argentina Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 91: Colombia Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 92: Colombia Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 93: Colombia Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 94: Colombia Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 95: Middle East & Africa Biosurgery Market Size and Forecast, By Product (2020 to 2031F) (In USD Billion)

Table 96: Middle East & Africa Biosurgery Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)

Table 97: Middle East & Africa Biosurgery Market Size and Forecast, By Source/Origin (2020 to 2031F) (In USD Billion)

Table 98: Middle East & Africa Biosurgery Market Size and Forecast, By End-User (2020 to 2031F) (In USD Billion)

Table 99: United Arab Emirates (UAE) Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 100: United Arab Emirates (UAE) Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 101: United Arab Emirates (UAE) Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 102: United Arab Emirates (UAE) Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 103: Saudi Arabia Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 104: Saudi Arabia Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 105: Saudi Arabia Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 106: Saudi Arabia Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 107: South Africa Biosurgery Market Size and Forecast By Product (2020 to 2031F) (In USD Billion)

Table 108: South Africa Biosurgery Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)

Table 109: South Africa Biosurgery Market Size and Forecast By Source/Origin (2020 to 2031F) (In USD Billion)

Table 110: South Africa Biosurgery Market Size and Forecast By End-User (2020 to 2031F) (In USD Billion)

Table 111: Competitive Dashboard of top 5 players, 2025

Table 112: Key Players Market Share Insights and Analysis for Biosurgery Market 2025